FOOD AND DRUG ADMINISTRATION (FDA)
Center for Biologics Evaluation and Research (CBER)
191st Meeting of the Vaccines and Related Biological Products Advisory Committee
Silver Spring, MD
March 12, 2026
DRAFT AGENDA

Topic: The Committee will meet in open session to discuss and make recommendations on the strain composition of influenza virus vaccines for use in United States during the 2026-2027 influenza season.

Time	Presentation/Presenter
9:00 am – 9:10 am	**Opening Remarks: Call to Order and Welcome (10 min)** **Arnold S. Monto, MD** Acting Chair, VRBPAC Thomas Francis Collegiate Professor of Public Health and Professor of Epidemiology University of Michigan School of Public Health
9:10 am – 9:30 am	**Administrative Announcements, Roll Call, Introduction of Committee, Conflict of Interest Statement (20 min)** **LCDR Cicely C. Reese, PharmD** Designated Federal Officer (DFO), VRBPAC Center for Biologics Evaluation and Research (CBER), FDA
9:30 am – 10:30 am	**Open Public Hearing (up to 60 min)**
10:30 am – 10:45 am	**Introduction (15 min)** **Jerry Weir, PhD (10 min)** Director, Division of Viral Products (DVP) Office of Vaccines Research and Review (OVRR) CBER, FDA Q & A: 5 min
10:45 am – 11:10 am	**U.S. Influenza Surveillance and Preliminary Vaccine Effectiveness Estimates, 2025-26 Season (25 min)** **Lisa Grohskopf, MD, MPH (20 min)** Medical Officer Epidemiology & Prevention Branch, Influenza Division Centers for Disease Control and Prevention (CDC) Q & A: 5 min
11:10 am – 11:20 am	**Break (10 min)**

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Biologics Evaluation and Research (CBER)
191st Meeting of the Vaccines and Related Biological Products Advisory Committee
Silver Spring, MD
March 12, 2026
DRAFT AGENDA

11:20 am – 12:30 pm	**<u>Global Influenza Virus Surveillance and Characterization</u> (70 min)** **Rebecca G. Kondor, PhD (60 min)** Interim Director, WHO Global Influenza Surveillance and Response (GISRS) Collaborating Center for Surveillance Epidemiology and Control of Influenza NCIRD Centers for Disease Control and Prevention Q & A: 10 min
12:30 pm – 1:00 pm	**Lunch (30 min)**
1:00 pm – 1:25 pm	**<u>Department of War Influenza Surveillance and Mid-Season Vaccine Effectiveness</u> (25 min)** **Bill Gruner, MS, MB (ASCP), CM (20 min)** Program Manager and Molecular Biologist at JYG Innovations United States Air Force School of Aerospace Medicine Wright-Patterson Air Force Base (WPAFB) Q & A: 5 min
1:25 pm – 1:45 pm	**<u>Candidate Vaccine Strains & Potency Reagents</u> (20 min)** **Manju Joshi, PhD (15 min)** Lead Biologist (Team Lead) Division of Biological Standards & Quality Control Office of Compliance and Biologics Quality CBER/FDA Q & A: 5 min
1:45 pm – 2:10 pm	**<u>Comments from Manufacturer Representative</u> (25 min)** **Beverly Taylor, PhD (20 min)** Head of Global Influenza Scientific Affairs CSL Seqirus Q & A: 5 min
2:10 pm – 3:30 pm	**Committee Discussion, Recommendations, and Vote (80 min)**
3:30 pm	**Closing Remarks and Adjournment**